Mr. Keelin has lead business, therapeutics area, and product strategy efforts for many of the top 20 biopharmaceutical companies. Over a 25-year career, Tom has helped many small but innovative companies achieve their potential through a unique combination of asset valuation, product development strategy, value-based deal negotiations support, and portfolio resource allocation. Tom co-founded the life sciences practice at Strategic Decision Group. He is also a co-author of "How SmithKline Beecham Makes Better Resource Allocation Decisions," Harvard Business Review, Mar-Apr '98.

Gilbert R. Mintz, Ph.D., President of GRM Associates, has 20-plus years in the biotechnology industry with expertise in business development and licensing. He has executed technology platform, corporate and academic collaborations and in/out licensing of late-stage products for partnerships in the US, Europe and Japan. He provides transactional and strategic planning advice to pre-IPO biotechnology companies. He has consulted for both therapeutic and tool-based companies, including Affymetrix, Aclara BioSciences and Spectral Genomics and has held senior management positions at Genelabs Technologies, Anergen (Corixa), Cygnus and Trega Biosciences. Dr. Mintz earned his Ph.D. from Washington University (St. Louis) and did post-doctoral training at The Johns Hopkins University School of Medicine in biochemistry.